ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO173

Impact of HIF Stabilizer ICA on Nrf2/Keap1 Pathway in Macrophages

Session Information

  • AKI: Mechanisms - III
    November 04, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

  • 103 AKI: Mechanisms


  • Kurzhagen, Johanna T., Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Bayern, Germany
  • Schauer, Max, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Bayern, Germany
  • Noel, Sanjeev, Johns Hopkins University, Baltimore, Maryland, United States
  • Rabb, Hamid, Johns Hopkins University, Baltimore, Maryland, United States
  • Willam, Carsten, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Bayern, Germany

Mice treated with HIF-stabilizer 2-(1-chloro-4-hydroxyisoquinoline-3-carboxamido) acetate (ICA) were protected from ischemia-reperfusion induced AKI, as were mice after treatment with Nrf2-inducer 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl] imidazole (CDDO-Im). However, the potential interactions of HIF and Nrf2/Keap1 pathways have not been studied in this context.


Bone marrow was isolated from wildtype (WT) and HIF1α-KO mice and differentiated into bone marrow-derived macrophages (BMDM). Cells were cultured for 5 days before treatment with vehicle, CDDO-Im (50nM), ICA (250µM) or CDDO-Im+ICA (50nM+250µM) for 24 hours. Cells were harvested and mRNA expression of Nrf2- (Nqo1) and HIF1α-target genes (Hmox1, Glut1, Ldha) using quantitative real time PCR was analyzed. Protein expression of Keap1, Nqo1 and HIF1α was studied by Western blotting. Statistical analyses were performed using one-way ANOVA and Dunnett post hoc test.


In BMDM from WT mice, treatment with CDDO-Im, ICA or the combination of both (CDDO-Im+ICA) resulted in an upregulation of Nqo1 mRNA expression (Vehicle: 1.3±0.2 vs. CDDO-Im: 4.4±1.3 (p<0.05); vs. ICA: 4.1±1.4 (p>0.05); vs. CDDO-Im+ICA: 4.4±1.5 (p<0.05)) and Hmox1 (Vehicle: 1.3±0.2 vs. CDDO-Im: 1.7±0.4 (p>0.05); vs. ICA: 5.0±1.3 (p>0.001); vs. CDDO-Im+ICA: 4.1±0.6 (p<0.001)). This effect was not reversed in HIF1α-KO cells for Nqo1 (Vehicle: 1.4±0.3 vs. CDDO-Im: 5.4±1.5 (p<0.001); vs. ICA: 3.9±0.1 (p<0.05); vs. CDDO-Im+ICA: 4.8±0.6 (p<0.01)). However, HIF1α-target genes Hmox1, Glut1 and Ldha were significantly upregulated by ICA treatment in WT mice, but not by CDDO-Im or vehicle treatment. Western blotting confirmed these results at the protein level with a decrease of Keap1 expression (Vehicle: 1 vs. ICA: 0.7±0.5) and an increase of Nqo1 expression (Vehicle: 1 vs. ICA: 1.3±0.4) in WT and HIF1α-KO mice.


These in vitro studies demonstrate an upregulation of the Nrf2-target gene Nqo1 following HIF-stabilizer, ICA, treatment. However, this effect was Hif1α independent. These results indicate a potential overlap of the two pathways HIF and Nrf2/Keap1 playing important roles in ischemic AKI. In vivo studies in AKI-models are warranted to assess the impact on these dual effects.


  • Government Support – Non-U.S.